Back to Search
Start Over
Phosphodiesterase 10A PET radioligand development program: from pig to human.
- Source :
-
Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2014 Apr; Vol. 55 (4), pp. 595-601. Date of Electronic Publication: 2014 Mar 10. - Publication Year :
- 2014
-
Abstract
- Unlabelled: Four novel phosphodiesterase 10A (PDE10A) PET tracers have been synthesized, characterized in preclinical studies, and compared with the previously reported (11)C-MP-10.<br />Methods: On the basis of in vitro data, IMA102, IMA104, IMA107, and IMA106 were identified as potential PDE10A radioligand candidates and labeled with either (11)C via N-methylation or with (18)F through an SN2 reaction, in the case of IMA102. These candidates were compared with (11)C-MP-10 in pilot in vivo studies in the pig brain. On the basis of these data, (11)C-IMA106 and (11)C-IMA107 were taken into further evaluation and comparison with (11)C-MP-10 in the primate brain. Finally, the most promising radioligand candidate was progressed into human evaluation.<br />Results: All 5 tracers were produced with good radiochemical yield and specific activity. All candidates readily entered the brain and demonstrated a heterogeneous distribution consistent with the known expression of PDE10A. Baseline PET studies in the pig and baboon showed that (11)C-IMA107 and (11)C-MP-10 displayed the most favorable tissue kinetics and imaging properties. The administration of selective PDE10A inhibitors reduced the binding of (11)C-IMA107 and (11)C-MP-10 in the PDE10A-rich brain regions, in a dose-dependent manner. In the nonhuman primate brain, the tissue kinetics of (11)C-IMA107 and (11)C-MP-10 were well described by a 2-tissue-compartment model, allowing robust estimates of the regional total volume of distribution. Blockade with unlabeled MP-10 confirmed the suitability of the cerebellum as a reference tissue and enabled the estimation of regional binding potential as the outcome measure of specific binding.<br />Conclusion: (11)C-IMA107 was identified as the ligand with the highest binding potential while still possessing reversible kinetics. The first human administration of (11)C-IMA107 has demonstrated the expected regional distribution and suitably fast kinetics, indicating that (11)C-IMA107 will be a useful tool for the investigation of PDE10A status in the living human brain.
- Subjects :
- Animals
Brain diagnostic imaging
Brain metabolism
Cerebellum diagnostic imaging
Cerebellum metabolism
Dose-Response Relationship, Drug
Heterocyclic Compounds, 2-Ring pharmacokinetics
Humans
Isotope Labeling methods
Papio
Quinoxalines pharmacokinetics
Radiopharmaceuticals pharmacokinetics
Swine
Tissue Distribution
Heterocyclic Compounds, 2-Ring chemical synthesis
Phosphoric Diester Hydrolases metabolism
Positron-Emission Tomography methods
Quinoxalines chemical synthesis
Radiopharmaceuticals chemical synthesis
Subjects
Details
- Language :
- English
- ISSN :
- 1535-5667
- Volume :
- 55
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 24614221
- Full Text :
- https://doi.org/10.2967/jnumed.113.131409